Targeting DNA Repair Pathways to Overcome Therapeutic Resistance

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 268 papers101 conceptsfrozen 2026-10-04

The fundamental goal of most cancer therapies—from ionizing radiation to platinum-based chemotherapy—is to induce lethal genomic instability. By shattering the DNA of rapidly dividing cells, these treatments trigger programmed cell death. However, the efficacy of this approach is constantly undermined by the cell’s own "internal repair shop": the DNA Damage Response (DDR).

Recent research across several cancer types suggests that therapeutic resistance is rarely a failure of the drug to reach its target, but rather a triumph of the tumor's repair mechanisms. By understanding how cancer cells hijack, restore, or over-activate these pathways, researchers are developing strategies to "break the repair shop" and re-sensitize resistant tumors.

The Tug of War Between Damage and Repair

When a patient receives platinum-based chemotherapy, the drug creates cross-links in the DNA that prevent replication. As Zhiqiang Gao and colleagues observed in non-small cell lung cancer (NSCLC), the success of this intervention depends heavily on the protein ERCC1. If a tumor expresses high levels of this repair enzyme, it can effectively "undo" the damage as fast as the chemotherapy can inflict it, rendering the treatment ineffective (ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer).

This principle extends to radiotherapy. Liang Qu and Yarui Zhang identified that the Non-Homologous End Joining (NHEJ) pathway acts as a rapid-response team for radiation-induced breaks. Their work shows that the tumor suppressor RPRM can actually sensitize tumors to radiation by triggering the degradation of DNA-PKcs, a critical component of the NHEJ machinery (RPRM (Reprimo) triggers SCF FBXW11 -mediated DNA-PKcs degradation to block non-homologous end joining and radiosensitize tumors). Without this repair "saboteur," the cancer cell simply stitches its genome back together and survives.

Reversion Mutations and the Restoration of Function

One of the most sophisticated ways tumors evade treatment is through "reversion mutations." This is particularly common in cancers treated with PARP inhibitors (PARPi), which are designed to exploit existing DNA repair deficiencies (like BRCA mutations) to induce synthetic lethality.

As L. Collet and Isabelle Ray-Coquard explain, tumors that were once vulnerable because they couldn't repair DNA can evolve secondary mutations that restore the open reading frame of the damaged repair genes. This "re-establishes" the repair pathway, making the tumor suddenly resistant to both PARP inhibitors and platinum-based drugs (BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer). This evolutionary escape hatch highlights why targeting a single repair pathway often leads to temporary success followed by aggressive recurrence.

Exploiting Backup Pathways and Error-Prone Repair

When primary, high-fidelity repair pathways (like Homologous Recombination) are blocked, cancer cells often become "addicted" to error-prone backup pathways to survive. This creates a new vulnerability.

Qun Li and Chi Ma have focused on DNA polymerase theta (Polθ), an enzyme that drives a backup repair process called microhomology-mediated end joining (MMEJ). In multiple myeloma, they found that inhibiting Polθ prevents the cancer from adapting to chemotherapy-induced damage, forcing the cells into "mitotic catastrophe" (Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma).

Similarly, Zhuoyi Fan and Jun Xu demonstrated that inhibiting Checkpoint kinase-1 (CHK1) overrides the cell's natural "pause and repair" signal. By forcing the cell to continue dividing while its DNA is still broken, the combination of CHK1 inhibitors and etoposide creates a synergistic lethal effect that overcomes standard drug resistance (Checkpoint kinase-1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia).

Precision Sensitization via Multi-Omics

The challenge for clinicians is identifying which repair pathway a specific patient's tumor is relying on. Irina Abécassis and Andrew J. Sedgewick used graphical modeling to show that specific genetic markers, such as the PARP1 rs1805407 variation, can predict whether a patient will respond to PARP inhibitors (PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells).

Furthermore, the DAISY trial, led by Fernanda Mosele and Fabrice André, recently identified mutations in the SLX4 DNA repair gene as a novel driver of resistance to antibody-drug conjugates (ADCs). Even if the antibody successfully delivers its toxic payload into the cell, mutations in SLX4 can prevent that payload from causing the intended DNA damage, allowing the tumor to survive (Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial).

Summary of the Intuition

The research direction is shifting from simply "hitting harder" with higher doses of toxins to "hitting smarter" by disabling the cell's ability to recover.

  1. Identify the Shield: Use biomarkers (like ERCC1 or SLX4) to see how the tumor is repairing itself.
  2. Remove the Shield: Use targeted inhibitors (like CHK1 or Polθ inhibitors) to disable those specific repair pathways.
  3. Deliver the Blow: Apply standard DNA-damaging agents (radiation, cisplatin, etoposide) to a now-defenseless cell.

By treating the DNA Damage Response as a targetable vulnerability rather than an immutable barrier, these researchers are turning the tumor's own survival mechanisms against it.

Papers in this version

Showing 60 of 68 papers.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 43 papers
  2. Version 1 · 2026-10-04 · 68 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_dna_repair_mediated_resistance_1e7a4f86,
  title = {DNA repair-mediated resistance},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/dna-repair-mediated-resistance/rdr_1e7a4f86560f42a894029c50cd9fb51e},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_targeting_dna_repair_pathways_to_overcom_1e7a4f86_v1,
  title = {Targeting DNA Repair Pathways to Overcome Therapeutic Resistance},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/targeting-dna-repair-pathways-to-overcome-therapeutic-resistance/rdr_1e7a4f86560f42a894029c50cd9fb51e/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}